thiazoles has been researched along with Hyperlipidemias in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 10 (18.52) | 18.2507 |
| 2000's | 37 (68.52) | 29.6817 |
| 2010's | 6 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adil, M; Ali, MR; Bawa, S; Paudel, YN; Sharma, M | 1 |
| Dai, G; Zhang, Y | 1 |
| Cho, SW; Dal Nam, K; Hahn, HG; Je Lee, W; Kim, EA; Yang, SJ; Young Choi, S | 1 |
| Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF | 1 |
| Elgire, RD; Mokale, SN; Sakle, N; Shinde, DB | 1 |
| Ackerman, U; Churilov, L; Donnan, GA; Gong, SJ; Gunawan, R; Ly, JV; Ma, H; O'Keefe, G; Rowe, CC; Sahathevan, R; Saunder, T; Tochon-Danguy, H; Villemagne, VL; Zavala, JA | 1 |
| Reusch, JE | 1 |
| Lebovitz, HE | 1 |
| Afaq, A; Blonde, L; Pathak, R | 1 |
| Montague, CT; Tugwood, JD | 1 |
| Kotake, H | 1 |
| Asnani, S; Fonseca, VA; Gouda, BP | 1 |
| Tan, MH | 1 |
| Viberti, GC | 1 |
| Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
| Chatterjee, VK; Gurnell, M; O'Rahilly, S; Savage, DB | 1 |
| Duran, S; Escobar-Jiménez, F; Godin, C; Grossman, LD; Hardin, PA; Hawkins, F; Herz, M; Johns, D; Konkoy, CS; Lochnan, H; Reviriego, J; Tan, MH | 1 |
| Ayyobi, AF; Brunzell, JD | 1 |
| Brown, RR; Estoup, MW | 1 |
| Dubois, D | 1 |
| Fu, J; Gaetani, S; Lin, E; Oveisi, F; Piomelli, D | 1 |
| Kostulski, A; Rabe-Jabłońska, J; Wyszogrodzka-Kucharska, A | 1 |
| Katayama, S | 1 |
| Arakawa, K; Ohta, T; Saku, K; Zhang, B | 1 |
| Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP | 1 |
| Howard, BV; Howard, WJ | 1 |
| Fonseca, VA; Granberry, MC | 1 |
| Bujo, H; Hikita, M; Kobayashi, J; Morisaki, N; Nagashima, I; Otabe, M; Saito, Y; Takahashi, K | 1 |
| Ginsberg, H; Plutzky, J; Sobel, BE | 1 |
| Hunabiki, A; Kasuga, M; Morita, S | 1 |
| Booth, AM; Caldwell, SH; Iezzoni, JC | 1 |
| Mabuchi, H; Yagi, K | 1 |
| Iwamoto, Y; Iwatani, M; Kamatani, N; Wasada, T | 1 |
| Kuzuya, H; Nakano, T; Yamada, K | 1 |
| Kadowaki, T | 1 |
| Daida, H; Sunayama, S; Watanabe, Y; Yamaguchi, H | 1 |
| DiTusa, L; Luzier, AB | 1 |
| Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A | 1 |
| Abe, S; Akiyama, T; Jia, DM; Otsuki, M; Tabaru, A | 1 |
| Bloomgarden, ZT | 1 |
| Tooke, J | 1 |
| Kitabchi, AE; Umpierrez, GE | 1 |
| Castro Cabezas, M; Erkelens, DW; Halkes, CJ | 1 |
| Marcus, AO | 1 |
| Burkey, BF; Chen, W; de Souza, CJ; Dong, M; Eckhardt, M; Gagen, K; Laurent, D | 1 |
| Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S | 1 |
| Al-Majali, K; Betteridge, DJ; Kaplan, F | 1 |
| Häring, H; Stumvoll, M | 1 |
| Funahashi, T; Hotta, K; Ishikawa, K; Kawamoto, T; Kihara, S; Kishino, BI; Kuriyama, H; Matsuzawa, Y; Mineo, I; Nakagawa, C; Nakamura, T; Nishida, M; Nishida, Y; Nishimura, T; Ohuchi, N; Takahashi, M; Tarui, S; Tokunaga, K; Watanabe, F; Yamashita, S | 1 |
| Ebihara, I; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C | 1 |
| Legro, RS | 1 |
| Fujita, T; Ikeda, H; Meguro, K; Shimura, Y; Sohda, T; Sugiyama, Y; Taketomi, S | 1 |
| Hosaka, Y; Matsushima, T; Muramatsu, M; Nagase, S; Niijima, T | 1 |
28 review(s) available for thiazoles and Hyperlipidemias
| Article | Year |
|---|---|
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Physical Fitness; Risk Factors; Thiazoles; Thrombosis; Vasodilation | 2002 |
Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metabolic Syndrome; Thiazoles | 2002 |
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin Resistance; Islets of Langerhans; Managed Care Programs; Mice; Outcome Assessment, Health Care; Thiazoles; Thiazolidinediones; United States | 2002 |
Biology and toxicology of PPARgamma ligands.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin Resistance; Ligands; Microbodies; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Zinc Fingers | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Effects of thiazolidinediones on cardiovascular risk factors.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrinolysis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Thiazoles; Vascular Resistance; Weight Gain | 2002 |
[Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].
Topics: Cardiovascular Diseases; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Pioglitazone; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Mutation; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Metabolic Syndrome; Niacin; Thiazoles; Thiazolidinediones | 2003 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles; Weight Gain | 2005 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Microvascular Angina; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Life Style; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1999 |
[Dyslipidemia in insulin resistance and its improvement by troglitazone].
Topics: Cholesterol, HDL; Chromans; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.
Topics: Chromans; Clinical Trials as Topic; Glucose; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Phenotype; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The association between insulin resistance and endotheliopathy.
Topics: Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Insulin Resistance; Syndrome; Thiazoles; Vasodilation | 1999 |
Management of type 2 diabetes. Evolving strategies for treatment.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Metformin; Sulfonylurea Compounds; Thiazoles | 2001 |
Obesity and free fatty acids: double trouble.
Topics: Chylomicrons; Coronary Artery Disease; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Obesity; Postprandial Period; Risk Factors; Thiazoles; Thiazolidinediones; Weight Loss | 2001 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Safety; Sulfonylurea Compounds; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
PPARS, insulin resistance and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
Insulin resistance and insulin sensitizers.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Insulin Secretion; Thiazoles | 2001 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diagnosis, Differential; Endometrial Neoplasms; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnancy; Progestins; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles; Thiazolidinediones | 2002 |
6 trial(s) available for thiazoles and Hyperlipidemias
| Article | Year |
|---|---|
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult | 2010 |
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Lipoproteins; Male; Middle Aged; Pioglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones; Treatment Outcome; United States | 2001 |
Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Body Composition; Cholesterol; Chromans; Double-Blind Method; Female; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin; Male; Middle Aged; Risk Factors; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2001 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Pioglitazone; Renal Dialysis; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
20 other study(ies) available for thiazoles and Hyperlipidemias
| Article | Year |
|---|---|
"2-(4-Fluorobenzamido)-4-methylthiazole-5-carboxylic acid" a novel thiazole compound, ameliorates insulin sensitivity and hyperlipidaemia in streptozotocin-induced diabetic rats: Plausible role of inflammatory and oxidative stress markers.
Topics: Animals; Benzamides; Biomarkers; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Experimental; Drinking; Feeding Behavior; Glucose Intolerance; Glycated Hemoglobin; Hyperlipidemias; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Kidney; Lipids; Liver; Organ Size; Oxidative Stress; Pancreas; Rats, Wistar; Streptozocin; Thiazoles; Toxicity Tests, Acute | 2017 |
Effects of N-adamantyl-4-methylthiazol-2-amine on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Glutathione; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Interleukin-1beta; Lipid Metabolism; Lipid Peroxidation; Liver; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Superoxide Dismutase; Thiazoles; Tumor Necrosis Factor-alpha; Vitamin E | 2014 |
Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.
Topics: Animals; Dietary Fats; Fibric Acids; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Propionates; Rats; Rats, Sprague-Dawley; Thiazoles | 2011 |
Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Atrial Fibrillation; Brain Infarction; Carbon Radioisotopes; Case-Control Studies; Diabetes Complications; Female; Humans; Hyperlipidemias; Hypertension; Male; Neocortex; Phenanthrolines; Positron-Emission Tomography; Risk Factors; Smoking; Stroke; Thiazoles | 2012 |
[Diabetes therapy. Blood vessel oriented rather than glucose-centered].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypoglycemic Agents; Thiazoles | 2002 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Electrocardiography; Female; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Olanzapine; Piperazines; Retrospective Studies; Schizophrenia; Thiazoles; Triglycerides | 2005 |
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Topics: Animals; Body Weight; Butyrates; CD36 Antigens; Cholesterol; Coenzyme A Ligases; Eating; Endocannabinoids; Fatty Acid-Binding Proteins; Hepatocytes; Hyperlipidemias; Ion Channels; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondrial Proteins; Obesity; Oleic Acids; Phenylurea Compounds; PPAR alpha; Pyrimidines; Rats; Rats, Inbred WF; Rats, Zucker; RNA, Messenger; Thiazoles; Thiazolidinediones; Triglycerides; Uncoupling Protein 2 | 2005 |
Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Blood Pressure; Chromans; Female; Heart Rate; Hyperlipidemias; Insulin; Insulin Resistance; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1998 |
LDL cholesterol and troglitazone therapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase.
Topics: 3T3 Cells; Adipocytes; Aged; Animals; Blood Glucose; Blotting, Northern; Chromans; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Lipoprotein Lipase; Liver; Male; Mice; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone-associated hepatic failure.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Hepatic Encephalopathy; Humans; Hyperlipidemias; Hypoglycemic Agents; Liver; Liver Failure; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Potential interaction between troglitazone and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Chromans; Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pyrroles; Retrospective Studies; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Fasting; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Topics: Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Chromans; Colon; Colonic Polyps; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Hyperlipidemias; Hypoglycemic Agents; Insulin; Liver; Male; Organ Size; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides; Troglitazone | 2000 |
American Diabetes Association 60th Scientific Sessions, 2000: thiazolidinediones, obesity, and related topics.
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Obesity; Societies, Medical; Thiazoles | 2001 |
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
Topics: Adipocytes; Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Cell Division; Cell Size; DNA; Fatty Acids, Nonesterified; Feeding Behavior; Female; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnetic Resonance Imaging; Obesity; Pioglitazone; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Thinness; Triglycerides; Weight Gain | 2001 |
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred Strains; Mice, Obese; Pioglitazone; Rats; Rats, Inbred Strains; Rats, Zucker; Species Specificity; Thiazoles; Thiazolidinediones | 1990 |
Low susceptibility of analbuminemic rats to induction of bladder cancer by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
Topics: Animals; FANFT; Hyperlipidemias; Male; Rats; Rats, Inbred Strains; Rats, Mutant Strains; Serum Albumin; Thiazoles; Urinary Bladder Neoplasms | 1985 |